Please enter the email address you used to register, then we will send you a link to choose a new password
On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), pur...
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate o...
-SEC Filing
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate o...
90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept fo...